摘要
目的:探讨恩替卡韦联合干扰素对乙肝肝硬化患者睡眠质量的影响。方法:选取2021年2月至2023年3月中国科技大学附属第一医院收治的住院治疗的乙肝肝硬化患者100例作为研究对象,按照随机数字表法分为观察组(n=50)和对照组(n=50)。对照组给予恩替卡韦治疗,观察组给予恩替卡韦和干扰素联合治疗。采用匹兹堡睡眠质量指数(PSQI)比较2组患者干预前后睡眠质量的变化,采用生命质量测定量表(QLQ-C30)比较2组患者干预前后的生命质量变化,并比较2组患者干预前后的不良反应。结果:干预后,观察组PSQI评分显著低于对照组,观察组QLQ-C30评分显著高于对照组,观察组不良反应发生率显著低于对照组,差异均有统计学意义(均P<0.05)。结论:恩替卡韦与干扰素结合应用,对慢性乙肝肝硬化患者来说可以改善其睡眠质量,提高其生命质量,具有较高的安全性,值得临床推广使用。
Objective:To investigate the effects of entecavir combined with interferon on sleep quality in patients with hepatitis B cirrhosis.Methods:A total of 100 patients with hepatitis B cirrhosis admitted to the First Affiliated Hospital of University of Science and Technology of China from February 2021 to March 2023 were selected as the study objects.They were divided into observation group(n=50)and control group(n=50)according to random number table method.The control group was treated with entecavir,and the observation group was treated with entecavir and interferon.Pittsburgh Sleep Quality Index(PSQI)was used to compare the changes of sleep quality before and after the intervention between the two groups,QLQ-C30 was used to compare the changes of life quality between the two groups before and after the intervention,and the adverse reactions between the two groups were compared.Results:After intervention,PSQI score in observation group was significantly lower than that in control group,QLQ-C30 score in observation group was significantly higher than that in control group,and the incidence of adverse reactions in observation group was significantly lower than that in control group,with statistical significance(P s<0.05).Conclusion:Entecavir combined with interferon can improve sleep quality and life quality of patients with chronic hepatitis B cirrhosis.It has high safety and is worthy of clinical promotion.
作者
郑韵
ZHENG Yun(First Affiliated Hospital of University of Science and Technology of China,Hefei 230000,China)
出处
《世界睡眠医学杂志》
2023年第8期1748-1750,共3页
World Journal of Sleep Medicine
